

HOW TO BEST USE IMMUNE CHECKPOINT INHIBITORS IN NSCLC: SINGLE AGENTS OR COMBINED WITH CHEMOTHERAPY?

ROOM A
PALEXPO, GENEVA,
SWITZERLAND

Chair
David Planchard, France

This educational activity is provided by
ESMO and supported by Lilly Oncology
in collaboration with MSD.

 **Lilly** | ONCOLOGY

 **MSD**

WEDNESDAY, 10 APRIL 2019
11:45 - 13:15

-
- 11:45 Introduction
David Planchard, Villejuif, France
 - 11:50 First-line immunotherapy options for patients
without an oncogene driver
Raffaele Califano, Manchester, UK
 - 12:10 What is the biological rationale for combining
chemotherapy with immune checkpoint inhibitors?
Marina Garassino, Milan, Italy
 - 12:30 Are immune checkpoints (ICPs) better as single
agent, doublet ICPs or combined with chemo +/-
anti-angiogenics?
Solange Peters, Lausanne, Switzerland
 - 12:50 Recommendation on second-line treatment
according to first-line choice
David Planchard, Villejuif, France
 - 13:10 Conclusion
David Planchard, Villejuif, France